ArticleOncoTargets and therapy2018
Quaternized chitosan promotes the antiproliferative effect of vemurafenib in melanoma cells by increasing cell permeability.
Article in OncoTargets and therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 7 citations in OpenAlex.
- Graphene oxide/gallium nanoderivative as a multifunctional modulator of osteoblastogenesis and osteoclastogenesis for the synergistic therapy of implant-related bone infection.Bioactive materials · 2023Article
- Biomedical Applications of Quaternized Chitosan.Polymers · 2021Review
- A single-cell identification and capture chip for automatically and rapidly determining hydraulic permeability of cells.Analytical and bioanalytical chemistry · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAs one of the most invasive cutaneous carcinomas among all types of skin cancer, malignant melanoma remains a severe challenge in oncology and plastic surgery. Selective small-molecule inhibitors of V600E-mutant B-Raf (vemurafenib, for instance) have demonstrated satisfactory therapeutic efficacy in melanoma patients. However, acquired resistance during the period of drug administration has limited their clinical application. MATERIALS AND
methodsIn the present study, human melanoma cells with the B-Raf
resultsOur results indicated that the addition of quaternized chitosan could promote the antiproliferative effect of vemurafenib in melanoma cells and could also promote the cell apoptosis of melanoma cells treated with vemurafenib. In addition, quaternized chitosan could increase cell permeability at early stages of co-culture, thus contributing to the improvement in intracellular drug uptake. Meanwhile, the majority of the negative surface charge of the cells was counteracted by the quaternized chitosan, indicating that the surface charge of melanoma cells was disturbed after the addition of quaternized chitosan.
conclusionThis study indicated that disturbance of the surface charge of the cell membrane by quaternized chitosan is an important mechanism involved in changes in cell permeability, which promote the antiproliferative effect of vemurafenib in melanoma cells. Our preliminarily investigation provides new insights into the improvement of clinical melanoma therapy in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.